Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to
Today is set to kick off with a welcome chair of healthcare at Economist Impact, Vivek Muthu, followed by a keynote speech on ‘Cancer control: Global perspectives and European solutions’ by
